Alnylam Pharmaceuticals
ALNY
#617
Rank
$32.40 B
Marketcap
$256.18
Share price
-1.66%
Change (1 day)
26.30%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Operating Margin for Alnylam Pharmaceuticals (ALNY)

Operating Margin as of July 2024 (TTM): -108.63%

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is -108.63%. At the end of 2022 the company had an Operating Margin of -108.63%.

Operating Margin history for Alnylam Pharmaceuticals from 2003 to 2023

Operating Margin at the end of each year

Year Operating Margin Change
2022-108.63%7.63%
2021-100.93%-41.86%
2020-173.60%-56.91%
2019-402.85%-60.33%
2018-1,015.48%86%
2017-545.95%-37.22%
2016-869.63%23.21%
2015-705.83%-10.92%
2014-792.32%306.56%
2013-194.88%11.54%
2012-174.73%150.82%
2011-69.66%62.06%
2010-42.98%-8.07%
2009-46.76%76.12%
2008-26.55%-83.16%
2007-157.61%7.45%
2006-146.68%-80.71%
2005-760.53%0.84%
2004-754.18%-93.51%
2003-11,618.18%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
-71.00%-34.64%๐Ÿ‡บ๐Ÿ‡ธ USA
37.68%-134.69%๐Ÿ‡บ๐Ÿ‡ธ USA
-88.19%-18.82%๐Ÿ‡บ๐Ÿ‡ธ USA
-36.36%-66.53%๐Ÿ‡บ๐Ÿ‡ธ USA
-119.48% 9.99%๐Ÿ‡บ๐Ÿ‡ธ USA
17.27%-115.90%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
18.21%-116.76%๐Ÿ‡ซ๐Ÿ‡ท France
-20.53%-81.10%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

What is a company's Operating Margin

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.